Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: Balance of breast risks and endometrial benefits - Systematic review of literature

Reproductive Sciences

Volumn 21, Issue 4, 2014, Pages 423-431

  Gizzo, Salvatore ^a   Di Gangi, Stefania ^a   Bertocco, Anna ^a   Noventa, Marco ^a   Fagherazzi, Simone ^a   Ancona, Emanuele ^a   Saccardi, Carlo ^a   Patrelli, Tito Silvio ^b   D'Antona, Donato ^a   Nardelli, Giovanni Battista ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

breast effects; endometrium effects; estrogen activity; estrogen receptor; progesterone effects

Indexed keywords

COPPER INTRAUTERINE DEVICE; LEVONORGESTREL; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; COHORT ANALYSIS; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; BLOOD; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; METABOLISM; PATHOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; ENDOMETRIUM; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899002895     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113503408     Document Type: Review

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 ; 61 (4). 212-236
2. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 ; 353 (17). 1784-1792 (Pubitemid 41549890)
3. Aebi S, Davidson T, Gruber G, Cardoso F. ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 ; 22 (suppl 6). 12 - vi
4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 ; 28 (16). 2784-2795
5. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010 ; 28 (3). 509-518
6. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009 ; ( 4 ):
7. Tamoxifen and uterine cancer. Obstet Gynecol. 2006 ; 107 (6). 1475-1478
8. Mattson L. Cost effectiveness in obstetrics and gynecology: the levonorgestrel intrauterine system. Minn Med. 2012 ; 95 (3). 51-54
9. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012 ; 27 (1). 122-131
10. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991 ; 51 (18). 4837-4844
11. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 ; 339 (22). 1609-1618 (Pubitemid 28536137)
12. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003 ; 9 (6). 1980-1989 (Pubitemid 36687616)
13. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011 ; 22 (4). 145-152
14. Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol. 2012 ; 357 (1-2). 101-107
15. Xu B, Kitawaki J, Koshiba H, et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas. 2007 ; 56 (2). 142-152 (Pubitemid 46073512)
16. Obr AE, Edwards DP. The biology of progesterone receptor in thenormal mammary gland and in breast cancer. Mol Cell Endocrinol. 2012 ; 357 (1-2). 4-17
17. Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000 ; 356 (9243). 1711-1717
18. Chan SS, Tam WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007 ; 114 (12). 1510-1515 (Pubitemid 350077441)
19. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric. 2008 ; 11 (3). 252-257
20. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel- releasing intrauterine system and breast cancer. Obstet Gynecol. 2005 ; 106 (4). 813-817 (Pubitemid 41362188)
21. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011 ; 83 (3). 211-217
22. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008 ; 90 (1). 17-22 (Pubitemid 351885178)
23. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010 ; 126 (2). 483-489
24. Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 ; 378 (9793). 771-784
25. Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010 ; 8 (10). 1112-1146
26. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 ; 97 (22). 1652-1662 (Pubitemid 41672231)
27. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 ; 90 (18). 1371-1388 (Pubitemid 28439961)
28. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002 ; 20 (11). 2758-2760
29. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004 ; 94 (2). 256-266 (Pubitemid 39024525)
30. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG. 2010 ; 117 (7). 879-884
31. Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009 ; 19 (6). 1068-1073
32. Kim MK, Yoon BS, Park H, et al. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer. 2011 ; 21 (4). 673-677
33. Shah MM, Wright JD. Management of endometrial cancer in young women. Clin Obstet Gynecol. 2011 ; 54 (2). 219-225
34. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 ; 203 (6). e1-547
35. Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv. 2012 ; 67 (11). 726-733
36. Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 ; 84 (2). 485-491 (Pubitemid 41125274)
37. Trinh XB, van Dam PA, Tjalma WA. Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance?. Maturitas. 2006 ; 55 (1). 94-95 (Pubitemid 44093929)
38. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol. 2013 ; 121 (5). 943-950
39. Saccardi C, Gizzo S, Patrelli TS, et al. Endometrial surveillance in Tamoxifen users: role, timing and accuracy of hysteroscopic investigation. Observational longitudinal cohort study. Endocr Relat Cancer. 2013 ; 20 (4). 455-462
40. Gizzo S, Saccardi C, Patrelli TS, et al. Update on Raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013 ; 68 (6). 467-481